Abstract
Thirteen major depressive patients not responding to a 4-week venlafaxine 300 mg treatment were eligible for a 4-week open trial of lithium addition. Two patients had to stop lithium for a possible moderate serotonin syndrome and five patients became responders, including one dramatic response and two semi-rapid responses.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antidepressive Agents / administration & dosage*
-
Antidepressive Agents / adverse effects
-
Cyclohexanols / administration & dosage*
-
Cyclohexanols / adverse effects
-
Delayed-Action Preparations
-
Depressive Disorder / diagnosis
-
Depressive Disorder / drug therapy*
-
Depressive Disorder / psychology
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Female
-
Humans
-
Lithium Compounds / administration & dosage*
-
Lithium Compounds / adverse effects
-
Male
-
Middle Aged
-
Personality Inventory
-
Sulfates / administration & dosage*
-
Sulfates / adverse effects
-
Treatment Outcome
-
Venlafaxine Hydrochloride
Substances
-
Antidepressive Agents
-
Cyclohexanols
-
Delayed-Action Preparations
-
Lithium Compounds
-
Sulfates
-
Venlafaxine Hydrochloride
-
lithium sulfate